KinergyCare is a Virginia-based startup and a Virginia Bio member that is requesting feedback from this community on a care coaching and coordination approach that focuses on the needs of patients with cardiovascular disease. We’re pioneering a new approach that combines patient data on health capabilities with a personalized intervention based on behavioral science. The result should be a more personalized clinical intervention and coaching approach that better ensures lasting behavioral change. We’re looking to talk with stakeholders such as cardiologists, nurses, care management teams, and administrators to learn more about the unmet needs. This outreach is part of our participation in the Spring cohort of the Roanoke Acceleration and Mentoring Program (RAMP), so we would really appreciate any help. Please help us by filling in this brief, 10 question survey. Also, if you have some guidance or can connect us with someone in your network that fits the above roles please contact KinergyCare CEO Art Spivy at aspivy@kinergycare.com or (571) 277-5373. Thanks for your help!
News
Recent News
06/02/2026
TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed
TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and …
06/02/2026
Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development
Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing, …
06/02/2026
GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row
The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business …